Medication gip glp1 agonist
Tirzepatide (Mounjaro / Zepbound)
by Eli Lilly
glp-1 gip weight-loss diabetes peptide injectable metabolic-health
About this product
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. By targeting two incretin hormones simultaneously, it often produces greater weight reduction than single-agonist GLP-1 drugs.
Sold as Mounjaro for diabetes management and Zepbound specifically for weight loss in adults with obesity or overweight with a related condition.